Morgan Stanley Cassava Sciences Inc Transaction History

Morgan Stanley

$1.59 Trillion
Q3 2025

A detailed history of Morgan Stanley transactions in Cassava Sciences Inc stock. As of the latest transaction made, Morgan Stanley holds 350,060 shares of SAVA stock, worth $966,165. This represents 0.0% of its overall portfolio holdings.

Number of Shares

350,060

Previous 450,547 22.3%

Holding current value

$966,165

Previous $815,000 24.91%

% of portfolio

0.0%

Previous 0.0%

25 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 14, 2025	SELL	$1.85 - $3.41 $185,900 - $342,660	-100,487 Reduced 22.3%	350,060 $1.02 Million
Q2 2025 Aug 15, 2025	BUY	$1.19 - $2.24 $88,294 - $166,201	74,197 Added 19.71%	450,547 $815,000
Q1 2025 May 15, 2025	BUY	$1.5 - $3.02 $165,240 - $332,683	110,160 Added 41.38%	376,350 $564,000
Q4 2024 Feb 14, 2025	SELL	$2.29 - $32.18 $580,180 - $8.15 Million	-253,354 Reduced 48.76%	266,190 $628,000
Q3 2024 May 14, 2025	BUY	$9.57 - $35.08 $3.41 Million - $12.5 Million	356,217 Added 218.1%	519,544 $15.3 Million

Q3 2024 Nov 14, 2024	BUY	$9.57 - $35.08 $3.41 Million - $12.5 Million	356,217 Added 218.1%	519,544 $15.3 Million
Q2 2024 May 14, 2025	SELL	$12.35 - $26.11 $1.27 Million - $2.69 Million	-102,863 Reduced 38.64%	163,327 $2.02 Million
Q2 2024 Oct 17, 2024	SELL	$12.35 - $26.11 $507,510 - $1.07 Million	-41,094 Reduced 20.1%	163,327 $2.02 Million
Q2 2024 Aug 14, 2024	SELL	$12.35 - $26.11 $507,510 - $1.07 Million	-41,094 Reduced 20.1%	163,327 $2.02 Million
Q1 2024 Oct 17, 2024	BUY	$18.44 - $26.41 $757,773 - $1.09 Million	41,094 Added 25.16%	204,421 $4.15 Million
Q1 2024 Aug 16, 2024	SELL	$18.44 - $26.41 $6.21 Million - $8.9 Million	-336,852 Reduced 62.23%	204,421 $4.15 Million
Q1 2024 May 15, 2024	SELL	$18.44 - $26.41 $6.21 Million - $8.9 Million	-336,852 Reduced 62.23%	204,421 $4.15 Million
Q4 2023 Aug 16, 2024	BUY	$12.64 - $30.11 $4.78 Million - $11.4 Million	377,946 Added 231.4%	541,273 $12.2 Million
Q4 2023 Feb 13, 2024	BUY	$12.64 - $30.11 $1.37 Million - $3.25 Million	108,032 Added 24.94%	541,273 $12.2 Million
Q3 2023 Nov 15, 2023	BUY	$16.64 - $25.32 $4.36 Million - $6.64 Million	262,092 Added 153.14%	433,241 $7.21 Million
Q2 2023 Aug 14, 2023	BUY	$21.59 - $27.88 $403,646 - $521,244	18,696 Added 12.26%	171,149 $4.2 Million
Q1 2023 May 15, 2023	SELL	$23.46 - $36.44 $1.48 Million - $2.3 Million	-62,982 Reduced 29.23%	152,453 $3.68 Million
Q4 2022 Feb 14, 2023	SELL	$27.82 - $44.16 $69,772 - $110,753	-2,508 Reduced 1.15%	215,435 $6.36 Million
Q3 2022 Nov 14, 2022	BUY	$16.33 - $51.06 $23,613 - $73,832	1,446 Added 0.67%	217,943 $9.12 Million
Q2 2022 Oct 27, 2022	BUY	$17.22 - $38.47 $1.19 Million - $2.65 Million	68,822 Added 46.6%	216,497 $6.09 Million
Q2 2022 Aug 15, 2022	BUY	$17.22 - $38.47 $1.19 Million - $2.65 Million	68,822 Added 46.6%	216,497 $6.09 Million
Q1 2022 Oct 27, 2022	SELL	$32.6 - $53.05 $2.24 Million - $3.65 Million	-68,822 Reduced 31.79%	147,675 $5.48 Million
Q1 2022 May 13, 2022	SELL	$32.6 - $53.05 $13.3 Million - $21.6 Million	-407,013 Reduced 73.38%	147,675 $5.48 Million
Q4 2021 Feb 14, 2022	BUY	$36.77 - $90.91 $7.36 Million - $18.2 Million	200,219 Added 56.48%	554,688 $24.2 Million
Q3 2021 Nov 15, 2021	BUY	$41.79 - $135.3 $14.8 Million - $48 Million	354,469 New	354,469 $22 Million

Others Institutions Holding SAVA

# of Institutions

136

Shares Held

15.9M

Call Options Held

1.26M

Put Options Held

791K

View Full List

About CASSAVA SCIENCES INC

Ticker SAVA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,097,900
Market Cap $111M
Description
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's...

More about SAVA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account